Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04998396 · ClinicalTrials.gov registry record · Phase 1
A Study of AAV9 Gene Therapy in Participants With Canavan Disease (CANaspire Clinical Trial)
A Phase 1 study of Canavan Disease, sponsored by Aspa Therapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 26
- Enrollment target
- 4
- Study locations
NCT04998396 is a Phase 1 study of Canavan Disease that is actively recruiting participants, run by Aspa Therapeutics. The registered enrollment target is 26 participants. The trial reports 4 study locations across 4 states.
The verdict
NCT04998396, a Phase 1 study of Canavan Disease, is actively recruiting participants, sponsored by Aspa Therapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 26 participants
- Enrollment target
- 4
- Study locations
Study Summary
The main objective of this trial is to evaluate the safety, tolerability, and pharmacodynamic activity of BBP-812, an investigational AAV9-based gene therapy, in pediatric participants with Canavan disease.
Conditions Studied
Interventions
- BIOLOGICAL AAV9 BBP-812
Study Locations (4)
California
- UCSF Benioff Children's Hospital Oakland - Oakland
Illinois
- Ann & Robert H. Lurie Children's Hospital of Chicago - Chicago
Massachusetts
- Massachusetts General Hospital (MGH); Center for Rare Neurological Diseases (CRND) - Boston
New York
- Weill Cornell Medicine; Division of Pediatric Neurology - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2021-09-08 |
| Est. Completion | 2030-10-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04998396
The ClinicalTrials.gov registry entry for NCT04998396 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Aspa Therapeutics, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Canavan Disease appearing as the primary indexed condition, and to 1 intervention - of which AAV9 BBP-812 is the first listed.
NCT04998396 reports 4 study locations spanning 4 distinct geographic areas - top geographies include California, Illinois, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT04998396 about?
NCT04998396 is a clinical study titled "A Study of AAV9 Gene Therapy in Participants With Canavan Disease (CANaspire Clinical Trial)". The main objective of this trial is to evaluate the safety, tolerability, and pharmacodynamic activity of BBP-812, an investigational AAV9-based gene therapy, in pediatric participants with Canavan disease.
What is the current status of trial NCT04998396?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 26 participants. The study started on 2021-09-08. Estimated completion is 2030-10-08.
What conditions does trial NCT04998396 study?
This clinical trial studies the following conditions: Canavan Disease.
What interventions are being tested in trial NCT04998396?
The interventions under investigation include: AAV9 BBP-812 (BIOLOGICAL).
Who is sponsoring clinical trial NCT04998396?
This trial is sponsored by Aspa Therapeutics, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04998396 being conducted?
This trial has 4 study locations across California, Illinois, Massachusetts, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Canavan Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.